OSLO, Norway--(BUSINESS WIRE)--Affitech AS, the human antibody therapeutics company announced today another successfully completed milestone in its long-term antibody discovery partnership with Peregrine Pharmaceuticals. At the 2008 Annual Meeting of the American Association for Cancer Research (AACR), Peregrine presented preclinical studies demonstrating that PGN635, a fully human antibody discovered as part of their collaboration, exhibits anti tumor efficacy by targeting phosphatidylserine (PS). Peregrine currently has an anti-PS antibody, bavituximab, that is in phase II clinical trials for the treatment of breast and lung cancers and in a phase I study for the treatment of chronic HCV infection.
